Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
Authors
Keywords
-
Journal
TOXICOLOGIC PATHOLOGY
Volume -, Issue -, Pages 019262332096807
Publisher
SAGE Publications
Online
2020-11-18
DOI
10.1177/0192623320968079
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- (2019) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Age-Related Macular Degeneration Preferred Practice Pattern®
- (2019) Christina J. Flaxel et al. OPHTHALMOLOGY
- RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2019) Frank G. Holz et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
- (2016) Maureen G. Maguire et al. OPHTHALMOLOGY
- Evaluating and Reporting the Immunogenicity Impacts for Biological Products—a Clinical Pharmacology Perspective
- (2015) Yow-Ming C. Wang et al. AAPS Journal
- Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study
- (2015) Jonathan L. Prenner et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration
- (2015) M Vukicevic et al. EYE
- Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti–Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration
- (2015) Marc C. Peden et al. OPHTHALMOLOGY
- Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
- (2015) Rishma Gohil et al. PLoS One
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
- (2014) Allen C. Ho et al. OPHTHALMOLOGY
- A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
- (2014) Sergio Pagliarini et al. Journal of Ophthalmology
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
- (2014) Wan Ling Wong et al. Lancet Global Health
- Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
- (2013) Peter J.K. van Meer et al. mAbs
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
- (2013) Soraya Rofagha et al. OPHTHALMOLOGY
- The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
- (2007) Tien Wong et al. OPHTHALMOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started